Table 1 Study, patient, disease, and primary treatment characteristics

From: Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data

Study characteristics Ford et al (2014) n (%) Thuss-Patience et al (2011) n (%) Kang et al (2012) n (%) Total
Total patient enrolment 168 40 202 410
Treatment details Docetaxel 75 mg m−2 every 3 weeks (n=84) vs SC (n=84) Irinotecan 250 mg m−2 cycle 1, thereafter up to 350 mg m−2 every 3 weeks (n=21) vs SC (n=19) Irinotecan 150 mg m−2 every 2 weeks (n=63) vs Docetaxel 65 mg m−2 every 2 weeks (n=70) vs SC (n=69)  
Maximum number of cycles 6 10 12  
Patient characteristics
Sex     
 Male 136 (81%) 29 (73%) 137 (68%) 302 (74%)
 Female 32 (19%) 11 (22%) 65 (32%) 108 (26%)
Age, years (median (range)) 65 (28–84) 58 (35–73) 56 (31–76) 59 (28–84)
 Age 70 129 (77%) 37 (93%) 182 (90%) 348 (85%)
 Age >70 39 (23%) 3 (7%) 20 (10%) 62 (15%)
ECOG PS     
 0 or 1 142 (84%) 31 (78%) 200 (99%) 373 (91%)
 0 46 (27%) 108 (53%) 154
 1 96 (57%) 92 (46%) 188
 2 26 (16%) 9 (22%) 2 (1%) 37 (9%)
Disease characteristics and previous treatment
Disease status     
 Locally advanced 21 (13%) 0 0 21 (5%)
 Metastatic disease 147 (87%) 40 (100%) 202 (100%) 389 (95%)
Site of primary disease     
 Oesophagus 33 (20%) 0 0 33 (8%)
 Oesophago-gastric junction 59 (35%) 17 (42%) 0 76 (18%)
 Stomach 76 (45%) 23 (58%) 202 (100%) 301 (73%)
Response to previous CT     
 CR 0 2 (5%) 4 (2%) 6 (1%)
 PR 29 (17%) 9 (22%) 79 (39%) 117 (29%)
 SD 42 (25%) 10 (25%) 26 (13%) 78 (19%)
 PD 91 (54%) 19 (48%) 89 (44%) 199 (49%)
 Non-evaluable 6 (4%) 0 4 (2%) 10 (2%)
Time between end of previous CT and documented PD     
 During treatment 72 (43%) 16 (40%) 74 (37%) 162 (39%)
 Within 3 months 49 (29%) 19 (48%) 75 (37%) 143 (35%)
 3–6 Months 47 (28%) 5 (12%) 53 (26%) 105 (26%)
Number of sites of PD     
 1 65 (39%) 17 (42%) 70 (35%) 152 (37%)
 2 or more 103 (61%) 23 (58%) 132 (65%) 258 (63%)
Previous surgery     
 No 127 (76%) 20 (50%) 158 (78%) 305 (74%)
 Yes 41 (24%) 20 (50%) 44 (22%) 105 (26%)
Previous radiotherapy     
 No 157 (93%) 40 (100%) 172 (85%) 369 (90%)
 Yes 11 (7%) 0 30 (15%) 41 (10%)
  1. Abbreviations: CR=complete response; PD=progressive disease; PR=partial response; PS=performance status; SD=stable disease.